通策医疗股份有限公司 2023年社会责任报告 通 时 达 变 策 发 真 智 通策医疗股份有限公司 TOPCHOICE MEDICAL CORPORATION 地址：浙江省杭州市灵溪北路21号合生国贸中心5号楼 邮编：310023 网址：www.tcmedical.com.cn 通策医疗股份有限公司 TOPCHOICE MEDICAL CORPORATION 2023 社会责任报告 关于本报告 关于本报告 本报告是通策医疗股份有限公司发布的第11份社会责任报告，对外披露本公司2023年在经济、社会、环境、公司治理 等方面的社会责任理念、实践和相关绩效。我们期望通过发布社会责任报告的方式，加强与利益相关方的沟通，凝聚 共识，促进可持续发展。 一、时间范围 本报告时间范围为2023年1月1日至2023年12月31日，部分内容超出上述范围。 二、组织范围 以通策医疗股份有限公司为主题包括所属分子公司及事业部等机构。 三、发布周期 通策医疗股份有限公司社会责任报告为年度报告。 四、数据说明 本报告所引用的数据，均来自于公司正式文件、统计报告或公开文件。 五、参考标准 本报告编写参照中国社科院《中国企业社会责任报告编写 ...

Financial Performance - The company recorded a revenue growth of only 4.7% in 2023, significantly lower than the initial expectation of 25% growth[3] - The company's operating revenue for 2023 was approximately ¥2.85 billion, an increase of 4.70% compared to ¥2.72 billion in 2022[16] - The net profit attributable to shareholders for 2023 was approximately ¥500.47 million, a decrease of 8.72% from ¥548.27 million in 2022[16] - The basic earnings per share for 2023 were ¥1.56, down 8.77% from ¥1.71 in 2022[17] - The weighted average return on equity for 2023 was 14.06%, a decrease of 3.51 percentage points from 17.57% in 2022[17] - The company reported a decrease in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to approximately ¥481.24 million in 2023, down 8.37% from ¥525.20 million in 2022[16] - The company's gross margin and net margin for 2023 were 39% and 20.32%, respectively[25] - The net profit attributable to shareholders was 500 million RMB, a decrease of 8.72% compared to the previous year[23] - The company achieved a main business revenue of 47,886 million in the planting segment, a 6.95% increase from 2022[27] - The orthodontics segment reported a revenue of 49,891 million, reflecting a decline of 3.14% compared to the previous year[27] Cash Flow and Investments - The net cash flow from operating activities increased by 25.36% to approximately ¥839.95 million in 2023, compared to ¥670.05 million in 2022[16] - Cash flow from operating activities increased to CNY 839,951,279.03, up from CNY 670,049,962.94, representing a growth of 25.3%[174] - Investment activities resulted in a net cash outflow of CNY 884,180,423.98, an increase of 77.78% year-on-year due to increased external investments[44] - The company reported a significant decrease in actual sales from related transactions, totaling 8,964.27 million RMB compared to an expected 16,160 million RMB[123] - The company reported a net cash outflow from investing activities of -884,180,423.98, an increase of 77.78% compared to the previous year[56] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of 4.35 yuan per 10 shares, totaling approximately 139.13 million yuan, which represents a cash dividend payout ratio of 47.98%[6] - The total cash dividend amount, including share buyback costs, is approximately 240.12 million RMB, representing 47.98% of the net profit attributable to ordinary shareholders for the year[106] Operational Changes and Strategy - The company has closed two dental hospitals in Chongqing and Chengdu due to high rental costs and is shifting its expansion strategy towards acquisitions and partnerships[4] - The company is adjusting its hospital layout to increase the supply of mid-to-low service products, with plans to integrate with Hangzhou Medical College[5] - The company is expanding its regional dental hospital groups, with new groups established in Hunan and Kunming, enhancing operational collaboration[29] - The company is advancing the "Dandelion Hospital" project, focusing on operational results and management evaluations to improve hospital performance[29] - The company aims to enhance operational capabilities through target management to achieve cost reduction and efficiency improvement[26] Market Trends and Consumer Behavior - The company acknowledges the "Pinduoduo effect" in the dental implant market, where price-sensitive consumers are misled into thinking dental implants are a simple commodity[4] - The overall demand for oral healthcare services in China is expected to exceed RMB 140 billion by 2024, with a CAGR of approximately 11.4% for the number of visits to dental specialty hospitals over the past five years[34] - The dental healthcare market is increasingly focusing on preventive care, with an emphasis on early intervention to reduce oral disease occurrences[63] - The dental healthcare consumer base is diversifying, with a growing focus on young and pediatric dental care[63] Risk Management and Compliance - The company has outlined potential risks in its annual report, which can be found in the discussion and analysis section[8] - The company recognizes the competitive risks in the dental market, particularly in the low-price segment, and will explore strategies to stabilize profitability while expanding[73] - Continuous improvement of medical quality management standards is a priority to mitigate medical risks and enhance patient safety[72] - The company actively completed rectification following the penalties and will enhance compliance with securities laws and regulations[89] Human Resources and Talent Management - The company has established a performance evaluation system for hospital management teams, focusing on financial and operational management indicators[100] - The company has implemented a comprehensive talent management strategy, including special compensation packages to attract and retain talent[100] - The company has a stable management team and a growing pool of technical talent with multi-disciplinary backgrounds and extensive industry experience[102] - The company has established a tiered incentive mechanism for its doctor partnership group to leverage expert resources for customer service[100] Acquisitions and Partnerships - The company approved the acquisition and capital increase proposal for Loudi Dental Hospital Co., Ltd. on December 11, 2023[96] - The company has exercised its right to acquire an additional 6% stake in Zhejiang Tongce Eye Hospital Investment Management Co., Ltd. for 120 million RMB, completing the transaction as of November 7, 2023[127] - The company is exploring potential acquisitions to enhance its service offerings, with a budget of 200 million RMB set aside for this purpose[81] Governance and Shareholder Relations - The company held 1 shareholders' meeting and 8 board meetings during the reporting period, discussing key matters including the 2022 annual report and profit distribution[75] - The company has maintained independence from its controlling shareholders in terms of assets, personnel, finance, and operations, ensuring a complete business system[77] - The company actively fulfills information disclosure obligations, enhancing the quality and accuracy of disclosed information[76] - The company has a dedicated team for investor relations, facilitating communication through various channels[76] Environmental and Social Responsibility - The company invested 10 million yuan in environmental protection during the reporting period[112] - The company has implemented various measures to reduce carbon emissions, including energy-saving practices and waste management systems[114] - The company has established a comprehensive environmental management network to enhance environmental awareness across all operational levels[113] Future Outlook - The company plans to expand its market presence and invest in new technologies to drive future growth[165] - The company aims to enhance brand awareness through an all-staff marketing initiative, encouraging employee participation in promotional activities[70] - The company aims to create a win-win situation for shareholders by providing lifetime services to customers while ensuring sustainable growth[71]

通策医疗股份有限公司（以下简称"公司"）聘请中汇会计师事务所（特殊 普通合伙）（以下简称"中汇会计师事务所"或"中汇所"）作为公司 2023 年度 出具审计报告的会计师事务所。根据财政部、国务院国有资产监督管理委员会、 中国证券监督管理委员会颁布的《国有企业、上市公司选聘会计师事务所管理办 法》，公司对中汇会计师事务所在 2023 年度的审计工作的履职情况进行了评估。 具体情况如下： 一、会计师事务所的情况 （一）基本情况 首席合伙人：余强； 上年度末（2023 年 12 月 31 日）合伙人数量：103 人； 上年度末（2023 年 12 月 31 日）注册会计师人数：701 人； 上年度末（2023 年 12 月 31 日）签署过证券服务业务审计报告的注册会计 师人数：282 人； 最近一年（2023 年度）经审计的收入总额：108,764 万元； 最近一年（2023 年度）审计业务收入：97,289 万元； 最近一年（2023 年度）证券业务收入：54,159 万元； 上年度（2022 年年报）上市公司审计客户家数：159 家。 上年度（2022 年年报）上市公司审计客户主要行业： 1 事务所名称：中汇 ...

通策医疗股份有限公司 2023 年度审计报告 中国杭州市线江新城新业趋8号UDC可代大直A座5-8雷、12剧、23厘 Floxes 5-3, 12 and 23, Block A. UOC Times Bislating, No. 8 Kmyn Read. Quanjiang News City Prangchase first, U571-88579991 Fax, 0571-388170000 www.zhopa.cn .您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查验 报告编码:浙24Z6R7HBYF 目 曼 | | 页 次 | | --- | --- | | 一、审计报告 | 1-5 | | 二、财务报表 | 6-17 | | (一) 合并资产负债表 | 6-7 | | (二) 合并利润表 | 8 | | (三) 合并现金流量表 | 9 | | (四) 合并所有者权益变动表 | 10-11 | | (五) 母公司资产负债表 | 12-13 | | (六) 母公司利润表 | 14 | | (七) 母公司现金流量表 | 15 | | (八) ...

通策医疗股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 www.zhcpa.cn 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查验 报告编码:浙24W6SPA1RV 内部控制审计报告 中汇会审[2024]5322号 通策医疗股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了通策医疗股份有限公司(以下简称通策医疗公司)2023年12月31日的财务 报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是通策 医疗公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上 ...

本人作为通策医疗股份有限公司（以下简称"公司"）的独立董事，本人严格 按照《中华人民共和国公司法》《关于在上市公司建立独立董事制度的指导意见》 《上市公司治理准则》等规章和《公司章程》等规定，本着"恪尽职守、勤勉尽责 "的工作态度，认真出席股东大会和董事会会议，认真审议董事会各项议案，积极 参加现场考察，并基于独立立场对相关事项发表独立客观的意见，切实维护了公司 和全体股东的合法利益，对促进董事会的科学决策、公司的规范运作和高质量发展 起到了积极作用。现将2023年度的履职情况报告如下： （一）个人履历 曹茂喜：男，1972年出生，中国国籍，无境外永久居留权，中共党员，硕士。厦 门大学金融学硕士，从事财务、审计、投资、咨询等相关工作26年。曾任职于浙华会 计师事务所、浙江中汇会计师事务所、证监会浙江监管局、国投创新投资管理有限公 司等，目前就职于浙江中会会计师事务所，担任通策医疗股份有限公司第九届董事独 立董事、物产中大集团股份有限公司独立董事。 （二）独立性说明 作为公司的独立董事，本人未在公司担任除独立董事外的其他职务，直系亲属、 主要社会关系均不在公司或其附属企业任职，没有为公司或其附属企业提供财务、法 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 708,442,365.10, representing a year-on-year increase of 5.03%[4] - The net profit attributable to shareholders for the same period was CNY 173,215,140.31, reflecting a growth of 2.51% compared to the previous year[4] - The basic earnings per share for Q1 2024 was CNY 0.54, showing a slight increase of 1.89%[4] - Total operating revenue for Q1 2024 reached ¥708,442,365.10, an increase of 5.5% compared to ¥674,535,941.41 in Q1 2023[18] - Net profit for Q1 2024 was ¥203,927,920.68, compared to ¥197,535,406.14 in Q1 2023, representing a growth of 3.2%[19] - Earnings per share for Q1 2024 were ¥0.54, slightly up from ¥0.53 in Q1 2023[20] Cash Flow and Investments - The net cash flow from operating activities decreased by 17.45%, amounting to CNY 129,407,477.28[4] - Cash flow from operating activities in Q1 2024 was ¥646,195,492.97, an increase from ¥615,794,420.54 in Q1 2023[21] - Total cash inflow from investment activities was $8,010,488.89, significantly lower than $164,522,177.12 in the previous period[22] - Cash outflow from investment activities totaled $157,560,127.05, compared to $211,046,930.77 in the previous period, indicating a reduction of 25.4%[22] - Net cash flow from financing activities was -$64,356,040.91, contrasting with a positive cash flow of $221,819,580.46 in the previous period[23] Assets and Liabilities - Total assets at the end of Q1 2024 reached CNY 6,091,919,301.07, a 1.43% increase from the end of the previous year[5] - The total liabilities as of Q1 2024 amounted to ¥1,759,365,241.63, down from ¥1,883,291,446.47 in the previous year[18] - The total current liabilities decreased to approximately CNY 512.56 million from CNY 644.69 million, a reduction of about 20.5%[17] - The total non-current assets reached approximately CNY 5.15 billion, up from CNY 5.04 billion, reflecting an increase of about 2.2%[17] Shareholder Equity - The equity attributable to shareholders increased by 4.50% to CNY 3,976,225,790.42 compared to the end of the previous year[5] - The total equity attributable to shareholders reached ¥3,976,225,790.42 in Q1 2024, compared to ¥3,805,042,375.87 in Q1 2023, reflecting an increase of 4.5%[18] Operational Metrics - Accounts receivable increased by 34.71%, primarily due to an increase in receivables from medical insurance and customer sales[8] - Goodwill rose by 45.31% due to the acquisition of Loudi Dental Hospital during the period[8] - The company received government subsidies amounting to CNY 2,096,628.62, which are closely related to its normal business operations[6] - The company reported an investment income of ¥12,329,246.39 in Q1 2024, compared to ¥9,093,068.14 in Q1 2023, indicating a significant increase of 35.5%[19] - Research and development expenses for Q1 2024 were ¥11,235,139.47, slightly higher than ¥11,077,832.40 in Q1 2023[19] Cash Management - The company's cash and cash equivalents decreased to approximately CNY 510.11 million from CNY 594.46 million, representing a decline of about 14.2%[16] - The ending balance of cash and cash equivalents was $509,582,218.44, down from $961,999,873.65 at the end of the previous period[23] - Cash paid for employee compensation increased to $304,031,478.13, up from $269,962,877.38, reflecting a rise of 12.6%[22] - Cash paid for taxes rose to $37,852,582.61, compared to $23,930,161.25, marking an increase of 58%[22] Accounting Standards - The company did not apply new accounting standards starting in 2024, maintaining consistency in financial reporting[24]

证券简称：通策医疗 证券代码：600763 编号：临 2024-031 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 通策医疗股份有限公司（以下简称"本公司"、"公司"）第十届监事会第二次会 议于 2024 年 4 月 25 日在公司会议室召开，监事会会议通知及相关文件以书面通知、 电话确认的方式通知全体监事。本次会议应出席监事 3 人，实际出席 3 人，会议由张 晓露先生主持，会议召集、召开程序符合《公司法》和《公司章程》的有关规定，合 法有效。 会议审议并通过以下议案： 通策医疗股份有限公司 第十届监事会第二次会议决议公告 一、审议通过《通策医疗股份有限公司 2023 年度报告》和《通策医疗股份有限 公司 2023 年度报告摘要》； 监事会对 2023 年年度报告的审核意见：公司监事会通过对公司 2023 年度报告编 制及编制过程的审核，认为《通策医疗股份有限公司 2023 年年度报告》的编制和审 议程序符合法律、法规、公司章程以及公司内部管理制度的各项规定；年度报告内容 和格式符合中国证监会和证券交易所的各项规定 ...

证券简称：通策医疗 证券代码：600763 编号：临 2024-034 通策医疗股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司拟续聘中汇会计师事务所（特殊普通合伙）担任公司 2024 年度财务和内 部控制审计机构。 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立于杭州， 系原具有证券、期货业务审计资格的会计师事务所之一，长期从事证券服务业务。 事务所名称：中汇会计师事务所（特殊普通合伙）； 最近一年（2023 年度）经审计的收入总额：108,764 万元； 最近一年（2023 年度）审计业务收入：97,289 万元； 最近一年（2023 年度）证券业务收入：54,159 万元； 上年度（2022 年年报）上市公司审计客户家数：159 家； 成立日期：2013 年 12 月 19 日； 组织形式：特殊普通合伙； 注册地址：杭州市上城区新业路 8 号华联时代大厦 A 幢 601 室； ...

证券简称：通策医疗 证券代码：600763 编号：临 2024-030 通策医疗股份有限公司 第十届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 通策医疗股份有限公司（以下简称"公司"）第十届董事会第二次会议通知以电 子邮件、电话等方式发出，会议于 2024 年 4 月 25 日在浙江省杭州市西湖区灵溪北路 21 号合生国贸中心 5 号楼会议室以现场表决方式召开。 本次会议由公司董事长王毅女士主持。会议应出席董事 7 人，实际出席 7 人，公 司监事以及公司高管列席本次会议，会议的通知、召开符合《公司法》、《公司章程》 及有关法律法规规定，会议决议合法有效。 二、董事会会议审议情况 会议审议并通过以下议案： 2、审议通过《通策医疗股份有限公司 2024 年第一季度报告》； 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《通策 1 医疗股份有限公司 2024 年第一季度报告》。 表决结果：7 票同意；0 票弃权；0 票反对。 本议案在提交董 ...